On this page
Rubinstein-Taybi syndrome
This multisystem condition affects development from birth, with most individuals experiencing moderate learning disability alongside characteristic physical features. The syndrome results from pathogenic variants in genes that regulate how other genes are switched on and off during early development.
Overview
Rubinstein-Taybi syndrome is a rare developmental disorder affecting approximately 1 in 100,000 to 125,000 births in the UK. The condition was first described in the 1960s and is characterised by a combination of distinctive physical features, developmental delay, and increased risk of certain health complications. Most people with this syndrome share a recognisable pattern of facial characteristics, broad thumbs and halluces (big toes), and learning disability of varying severity.
The syndrome affects multiple body systems, though the degree of impact varies considerably between individuals. While many features are present from birth, the full clinical picture often becomes clearer during early childhood as developmental milestones are monitored. Early recognition and diagnosis allow families to access appropriate support services and enable healthcare professionals to monitor for associated complications. The condition occurs equally in males and females and affects all ethnic groups.
The vast majority of cases arise from new (de novo) pathogenic variants - the genetic alteration occurs for the first time in the affected individual rather than being inherited from a parent. This pattern accounts for why parents of a child with Rubinstein-Taybi syndrome typically have no family history of the condition. Understanding the genetic basis helps inform recurrence risks for families and guides clinical management approaches.
Symptoms & clinical features
The clinical features of Rubinstein-Taybi syndrome typically include distinctive facial characteristics that become more recognisable with age. These often comprise a beaked nose with the nasal septum extending below the nostrils, highly arched eyebrows, long eyelashes, downward-slanting palpebral fissures (eye openings), and a characteristic smile. The face may appear small relative to the skull, and some individuals have a high-arched palate or dental crowding. These facial features help clinicians recognise the syndrome, though they vary in prominence between affected individuals.
Broad thumbs and halluces (big toes) with radial deviation are hallmark physical signs, present in most but not all cases. The broadening results from abnormal bone development in the distal phalanges. Some individuals also have extra (supernumerary) fingers or toes, whilst others show overlapping toes or other skeletal differences. Short stature is common, with many children tracking below typical growth centiles from early life. Feeding difficulties during infancy are frequently reported, sometimes necessitating specialised feeding support.
Developmental delay affects virtually all individuals with this syndrome, though the degree varies from mild to severe learning disability. Speech and language development is often particularly delayed, with many children requiring speech therapy and alternative communication strategies. Motor milestones such as sitting, walking and fine motor skills are typically achieved later than expected. Behavioural features may include attention difficulties, repetitive behaviours, and social challenges that sometimes meet criteria for autism spectrum disorder. Many individuals have a friendly, sociable personality despite communication challenges.
Video: Genetics 101
Affected organs
The syndrome can affect multiple organ systems beyond the characteristic facial and skeletal features. Cardiac abnormalities occur in a substantial proportion of individuals, ranging from relatively minor defects such as small atrial or ventricular septal defects to more complex congenital heart disease requiring surgical intervention. Echocardiography is typically performed in newly diagnosed individuals to identify any structural heart problems that need monitoring or treatment.
Eye problems are frequently encountered and may include refractive errors, strabismus (squint), blocked tear ducts, ptosis (drooping eyelid), and colobomas (gaps in eye structures). Regular ophthalmology review is recommended to optimise vision, as untreated visual problems can compound developmental challenges. Kidney and urinary tract abnormalities are identified in some individuals, whilst others experience recurrent infections or constipation. Growth and endocrine issues sometimes emerge, with some children showing delayed puberty or requiring growth hormone assessment. An increased tumour risk, though still relatively low in absolute terms, suggests surveillance for certain childhood cancers forms part of clinical management protocols in some centres.
Risks & severity
The severity of Rubinstein-Taybi syndrome varies considerably between individuals, even among those with pathogenic variants in the same gene. Learning disability is typically in the moderate range, though some individuals function in the mild range whilst others have severe intellectual impairment. This variability makes it difficult to predict outcomes for newly diagnosed infants, though developmental progress can be supported through early intervention therapies and educational support tailored to individual needs.
Individuals with this syndrome face an increased risk of developing certain tumours, particularly during childhood and adolescence. Evidence suggests the lifetime cancer risk may be elevated compared with the general population, with neural tumours, leukaemia, and other malignancies reported more frequently than expected. Whilst the absolute risk remains relatively low and most individuals do not develop cancer, this increased susceptibility informs surveillance recommendations in some protocols. The lifespan for people with Rubinstein-Taybi syndrome depends largely on the presence and severity of associated medical complications, particularly cardiac defects, though many individuals reach adulthood with appropriate medical care and support.
Genetic causes
Rubinstein-Taybi syndrome results from pathogenic variants in genes encoding proteins that regulate chromatin structure and gene expression. A substantial proportion of clinically diagnosed cases are caused by variants in CREBBP. This gene produces CREB binding protein, which serves as an essential controller of gene activity across tissues throughout the body. The protein regulates cellular growth, division, and specialisation - processes critical for typical development both before and after birth.
Another gene associated with this syndrome is EP300, which encodes a protein with closely related functions to CREBBP. The EP300 protein also acts as a lysine acetyltransferase and transcriptional regulator, controlling gene expression patterns during embryonic development and beyond. Both proteins work by modifying chromatin structure through acetylation, making DNA more accessible to the cellular machinery that reads genetic information. When either protein is absent or non-functional due to pathogenic variants, the coordinated gene expression patterns required for normal development are disrupted.
The pathogenic variants identified in these genes are typically loss-of-function changes - deletions, nonsense variants, or frameshift variants that prevent production of functional protein. Some individuals have whole-gene deletions detectable by chromosomal microarray analysis, whilst others carry smaller intragenic variants identified through sequencing. A proportion of clinically diagnosed individuals do not have identifiable pathogenic variants in CREBBP or EP300 with current testing methods, suggesting additional genetic causes remain to be discovered or that some variants in regulatory regions are missed by standard testing approaches.
- CREBBP CREB binding lysine acetyltransferaseThe CREBBP gene provides instructions for the CREB binding protein, which is crucial for gene regulation, cellular growth, differentiation, and brain development.
- EP300 EP300 lysine acetyltransferase
Inheritance pattern
Rubinstein-Taybi syndrome follows an autosomal dominant inheritance pattern, which indicates that a pathogenic variant in just one copy of CREBBP or EP300 is sufficient to cause the condition. However, the vast majority of cases arise from de novo variants, where the genetic change occurs for the first time in the affected individual. In these situations, neither parent carries the pathogenic variant, and the recurrence risk for future pregnancies is very low, though slightly higher than the general population risk due to the theoretical possibility of germline mosaicism.
Very rarely, an affected individual may inherit the pathogenic variant from a mildly affected or mosaic parent. Even more rarely, an affected adult may have children, in which case each pregnancy carries a 50% chance of inheriting the familial pathogenic variant. The clinical features in such families can vary considerably, even among relatives carrying the same variant, demonstrating that additional genetic and environmental factors influence how the syndrome manifests. Genetic counselling is recommended for all families following diagnosis to discuss recurrence risks, reproductive options, and implications for extended family members.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of Rubinstein-Taybi syndrome typically begins with clinical recognition of the characteristic facial features, broad thumbs and toes, and developmental delay. Paediatricians or clinical geneticists may suspect the diagnosis based on physical examination findings, though the features can be subtle in infancy and become more apparent with age. Confirmation requires genetic testing to identify a pathogenic variant in CREBBP or EP300.
Genetic testing approaches include chromosomal microarray analysis to detect larger deletions encompassing CREBBP or EP300, followed by sequencing of these genes if microarray testing is negative. Some laboratories employ gene panel testing that includes both genes alongside others associated with overlapping syndromes. Testing is typically arranged through NHS clinical genetics services following referral by a paediatrician or other specialist. The condition is included in NHS Genomic Medicine Service testing pathways, with PanelApp panels incorporating CREBBP and EP300 for relevant clinical indications. Even with comprehensive genetic testing, a proportion of clinically diagnosed individuals do not have an identifiable pathogenic variant, representing either limitations of current testing technology or unidentified genetic causes.
Management & lifestyle
Management of Rubinstein-Taybi syndrome requires coordinated multidisciplinary care addressing developmental, medical, and psychosocial needs. Early intervention services including physiotherapy, occupational therapy, and speech and language therapy can optimise developmental progress. Educational support tailored to individual learning profiles helps children reach their potential, with most requiring special educational provision. Regular monitoring for associated complications forms a core component of care, though specific surveillance protocols may vary between centres.
Cardiac assessment with echocardiography is typically performed at diagnosis, with ongoing cardiology follow-up determined by findings. Ophthalmology review monitors for visual problems requiring treatment, whilst dental care addresses tooth crowding and other oral health issues. Some families and clinicians follow published guidelines suggesting periodic surveillance for tumours during childhood and adolescence, though the optimal screening approach remains debated given the rarity of the condition and relatively low absolute cancer risk. Growth monitoring and assessment for endocrine problems may be warranted if concerns arise.
Genetic counselling provides families with information about the genetic basis, inheritance patterns, recurrence risks, and reproductive options. Connecting with support groups can help families access peer support and share practical strategies. Management decisions should be individualised based on each person's specific features and needs, with input from the individual and family where possible. Transition planning during adolescence helps prepare young adults and their families for adult healthcare services, housing, and social care needs.
UK care pathway
Within the NHS Genomic Medicine Service, individuals with suspected Rubinstein-Taybi syndrome are typically referred to clinical genetics services by paediatricians or other specialists. The relevant PanelApp resources include genes associated with intellectual disability and related developmental disorders. Genetic testing may be accessed through local genetics laboratories, with CREBBP and EP300 analysis available as part of relevant gene panels. The R-code system used for classifying rare diseases within NHS England includes appropriate codes for documenting this diagnosis.
Families can access genetic counselling through NHS clinical genetics departments, where counsellors provide detailed information about the condition, discuss test results and their implications, and explore reproductive options for future pregnancies if desired. Paediatric services coordinate multidisciplinary care during childhood, with adult services assuming responsibility after transition. Support is also available through voluntary organisations and patient support groups that provide information resources, connect families, and sometimes fund research into rare developmental conditions.
Frequently asked questions
Will my child with Rubinstein-Taybi syndrome be able to live independently as an adult?
The degree of independence varies considerably between individuals and depends largely on the severity of learning disability and any associated medical complications. Some adults with milder learning disability live semi-independently with support, whilst others require more comprehensive care. Early intervention, appropriate education, and skill-building during childhood and adolescence help maximise independence, though many adults will need ongoing support with daily living activities, employment, and healthcare management.
What is the cancer risk for someone with this syndrome and should we do screening?
Evidence suggests individuals with Rubinstein-Taybi syndrome have an increased risk of certain childhood tumours compared with the general population, though the absolute risk remains relatively low and most affected individuals never develop cancer. Some specialists recommend periodic surveillance during childhood and adolescence, though protocols vary between centres and families should discuss the potential benefits and limitations of screening with their clinical team.
If our child has Rubinstein-Taybi syndrome from a de novo variant, what is the chance of having another affected child?
When the pathogenic variant arose de novo in your child and neither parent carries it in their blood, the recurrence risk for future pregnancies is very low, slightly higher than the general population risk. This small residual risk exists because of the theoretical possibility of germline mosaicism, where a parent might carry the variant in some reproductive cells but not in blood cells tested. Genetic counselling can provide personalised risk assessment based on your specific situation.
Are there treatments that can cure Rubinstein-Taybi syndrome or reverse the learning disability?
Currently there is no cure for Rubinstein-Taybi syndrome, and the learning disability cannot be reversed, as it results from altered development of the brain before and after birth. However, early intervention therapies, educational support, speech and language therapy, and management of associated medical problems can significantly improve quality of life, help individuals reach their developmental potential, and address treatable complications. Research continues into understanding the condition better, which may eventually lead to new therapeutic approaches.
Should my child with Rubinstein-Taybi syndrome avoid any particular activities or medications?
There are no universal activity restrictions for all individuals with this syndrome, though specific limitations may apply depending on individual medical issues such as heart defects or skeletal problems. Any concerns about activities, sports participation, or specific medications should be discussed with your child's medical team, who can provide advice based on your child's particular features. Never stop or start any medication without consulting your doctor first, and ensure all healthcare providers are aware of the diagnosis so they can tailor care appropriately.
References
- Lacombe D, Bloch-Zupan A, Bredrup C. Diagnosis and management in Rubinstein-Taybi syndrome: first international consensus statement. Journal of medical genetics. 2024. PMID: 38471765
- Adam MP, Bick S, Mirzaa GM. Rubinstein-Taybi Syndrome. 1993. PMID: 20301699
- Hutchinson DT, Sullivan R. Rubinstein-Taybi Syndrome. The Journal of hand surgery. 2015. PMID: 26143027
- Hennekam RC. Rubinstein-Taybi syndrome. European journal of human genetics : EJHG. 2006. PMID: 16868563
- Korzus E. Rubinstein-Taybi Syndrome and Epigenetic Alterations. Advances in experimental medicine and biology. 2017. PMID: 28523540
- Kosaki R. Rubinstein-Taybi syndrome. Nihon rinsho. Japanese journal of clinical medicine. 2017. PMID: 30566799
- Cammarata-Scalisi F, Diociaiuti A, Cárdenas Tadich A. Dermatological findings in Rubinstein-Taybi Syndrome. Italian journal of dermatology and venereology. 2023. PMID: 37282850
- Boot MV, van Belzen MJ, Overbeek LI. Benign and malignant tumors in Rubinstein-Taybi syndrome. American journal of medical genetics. Part A. 2018. PMID: 29359884